SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $34,703,918 | -31.6% | 2,390,077 | -1.4% | 2.36% | -39.9% |
Q2 2023 | $50,737,083 | +5.6% | 2,424,132 | +6.6% | 3.92% | -13.9% |
Q1 2023 | $48,037,693 | -3.4% | 2,274,512 | +16.4% | 4.55% | -22.0% |
Q4 2022 | $49,742,330 | +90.8% | 1,954,512 | +80.1% | 5.84% | +68.0% |
Q3 2022 | $26,076,000 | +54.7% | 1,085,142 | +23.9% | 3.48% | +3.4% |
Q2 2022 | $16,857,000 | +38.3% | 876,156 | +24.9% | 3.36% | +4.3% |
Q1 2022 | $12,190,000 | +22.9% | 701,356 | +54.8% | 3.22% | +13.8% |
Q4 2021 | $9,918,000 | – | 453,091 | – | 2.83% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |